Eikon Therapeutics Inc is a publicly traded company operating in the Biotechnology industry. Its shares trade on NASDAQ NMS - GLOBAL MARKET under the ticker EIKN, with a market capitalization of approximately $679 million. A full business summary isn’t available for this company yet — the figures and signals on this pa…
An institutional-grade, numbers-driven thesis on EIKN — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Eikon Therapeutics Inc (EIKN) 54/100 with a 12-month base-case forecast of $8.03 — -36.0% versus the current price of $12.54. Eikon Therapeutics Inc trades at $12.54 in the Biotechnology sector, with a market capitalisation of $678.9M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for EIKN is $8.03, implying -36.0% versus the current price. The model's 12-month scenario range runs from $4.24 (bear) to $13.30 (bull), with a base case of $8.03.
On the fundamentals, Eikon Therapeutics shows trailing revenue of $0. This page also tracks EIKN's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
EIKN currently carries a TradersQuant composite score of 54/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "buy". Our 12-month price target of $8.03 implies -36.0% from $12.54. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for EIKN is $8.03, about -36.0% versus the latest price of $12.54. Consensus is based on 12 analysts.
TradersQuant's 12-month model forecast for EIKN is a base case of $8.03, ranging from $4.24 (bear) to $13.30 (bull), an expected return of -36.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for EIKN over the next 12 months is $8.03 in the base case (bear $4.24, bull $13.30), versus today's price of $12.54. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for EIKN — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates EIKN's fair value at $15.91, implying +26.9% of expected upside versus the current price.
Eikon Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
